Session Title: AMD II
Session Date/Time: Friday 27/09/2013 | 08:00-10:00
Paper Time: 08:56
Venue: Hall 3 (Level 0)
First Author: A.Filloy SPAIN
Co Author(s): M. Abia L. Arias
To study the changes in visual acuity (VA) in patients with retinal angiomatous proliferation (RAP) treated with intravitreal injections of ranibizumab in monotherapy.
The population of patients with RAP who have undergone treatment with intavitreal ranibizumab in our hospital.
Retrospective study. All patients were evaluated with a complete ophthalmologic examination including VA measurement with ETDRS charts, fluorescein angiography and optical coherence tomography (OCT). The treatment protocol consisted of an initial loading dose of three consecutive monthly injections followed by a Pro Re Nata (PRN) regimen where retreatment was given in the presence of VA loss and persistent or recurrent intraretinal or subretinal fluid on OCT scans.
The study included 43 eyes of 37 patients with a mean age of 77.6 years (SD : 6.84 ; 63-89). The average follow-up was 20 months (SD : 9.85; 6-39). The RAP stage was RAP 1 in 15 eyes ( 34.8%) RAP 2 in 27 eyes (62.8%) and RAP 3 in 1 eye (2.3%). The mean number of injections administered was 6 The mean initial VA was of 44.70 letters and the mean final VA was of 44.60 letters (p=0.01). No relevant systemic or ocular effects were noted.
Intravitreal injections of ranibizumab allow stabilization of VA after 2 years of follow-up.